Ország: Örményország
Nyelv: angol
Forrás: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
fentanyl
Acino AG
N02AB03
fentanyl
50mcg/h
patch transdermal
(5) patches
Prescription
Registered
2022-05-11
V030 – May 2019 (PSUSA) SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Fentavera 12.5 micrograms/hour transdermal patch Fentavera 25 micrograms/hour transdermal patch Fentavera 50 micrograms/hour transdermal patch Fentavera 75 micrograms/hour transdermal patch Fentavera 100 micrograms/hour transdermal patch 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Fentavera 12.5 micrograms/hour: 1 transdermal patch contains 2.55 mg fentanyl in a patch size of 4.25 cm 2 and releases 12.5 micrograms fentanyl per hour. Fentavera 25 micrograms/hour: 1 transdermal patch contains 5.1 mg fentanyl in a patch size of 8.5 cm 2 and releases 25 micrograms fentanyl per hour. Fentavera 50 micrograms/hour: 1 transdermal patch contains 10.2 mg fentanyl in a patch size of 17 cm 2 and releases 50 micrograms fentanyl per hour. Fentavera 75 micrograms/hour: 1 transdermal patch contains 15.3 mg fentanyl in a patch size of 25.5 cm 2 and releases 75 micrograms fentanyl per hour. Fentavera 100 micrograms/hour: 1 transdermal patch contains 20.4 mg fentanyl in a patch size of 34 cm 2 and releases 100 micrograms fentanyl per hour. Excipient with known effect: soya oil (Ph.Eur.) For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Transdermal patch. Fentavera is an opaque, colourless, rectangular-shaped patch with round corners and imprint on the backing foil: “Fentanyl 12 µg/h” for Fentavera 12.5 micrograms/hour “Fentanyl 25 µg/h” for Fentavera 25 micrograms/hour “Fentanyl 50 µg/h” for Fentavera 50 micrograms/hour “Fentanyl 75 µg/h” for Fentavera 75 micrograms/hour “Fentanyl 100 µg/h” for Fentavera 100 micrograms/hour 4. CLINICAL PARTICULARS V030 – May 2019 (PSUSA) 4.1 THERAPEUTIC INDICATIONS Adults Fentavera is indicated for management of severe chronic pain that requires continuous long-term opioid administration. Children Long-term management of severe chronic pain in children from 2 years of age who are already receiving opioid therapy. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Po Olvassa el a teljes dokumentumot